Literature DB >> 24711315

Alzheimer's disease legislation and policy--now and in the future.

David Hoffman.   

Abstract

Recent studies have pointed to the large and increasingly complex issues surrounding dementia in American society in general and health care in particular. The initial foray into the federal policy arena, the National Alzheimer's Project Act, is a good first step but remains limited in scope and resources. Seeing the need for greater effort, thirty-three states have convened advisory groups and published their own plans for coordinating state-level activity to address Alzheimer's disease across service systems. This article examines the current federal and state policy statements on dementia-related issues and offers an outlook and suggestions for next steps along with the imperative for action on a significant scale. This is necessary to address issues in a meaningful way today instead of simply holding out hope for a treatment or cure in the future. Dementia in general and Alzheimer's disease in particular affect individuals and every facet of families, health care, business, states, and communities. While public policy statements at all levels call for increased coordination of resources, better communication, awareness, and essential linkages, more effort is required.

Entities:  

Keywords:  Alzheimers; Chronic Care; Consumer Issues; Federal Policy; State Policy

Mesh:

Year:  2014        PMID: 24711315     DOI: 10.1377/hlthaff.2013.1223

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  Direct medical expenditures associated with Alzheimer's and related dementias (ADRD) in a nationally representative sample of older adults - an excess cost approach.

Authors:  Arijita Deb; Usha Sambamoorthi; James Douglas Thornton; Bernard Schreurs; Kim Innes
Journal:  Aging Ment Health       Date:  2017-02-08       Impact factor: 3.658

2.  A Call to Preventive Action by Health Care Providers and Policy Makers to Support Caregivers.

Authors:  David Hoffman; Howard Zucker
Journal:  Prev Chronic Dis       Date:  2016-07-21       Impact factor: 2.830

3.  Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease.

Authors:  Massimo S Fiandaca; Xiaogang Zhong; Amrita K Cheema; Michael H Orquiza; Swathi Chidambaram; Ming T Tan; Carole Roan Gresenz; Kevin T FitzGerald; Mike A Nalls; Andrew B Singleton; Mark Mapstone; Howard J Federoff
Journal:  Front Neurol       Date:  2015-11-12       Impact factor: 4.003

4.  Routine Check-Ups and Other Factors Affecting Discussions With a Health Care Provider About Subjective Memory Complaints, Behavioral Risk Factor Surveillance System, 21 States, 2011.

Authors:  Mary Adams
Journal:  Prev Chronic Dis       Date:  2016-01-28       Impact factor: 2.830

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.